Global Health (MEDANTA) Q4 25/26 earnings summary

Executive summary

• Achieved strong operational and financial performance in FY 2026, with 20% revenue and 15.1% PAT growth, driven by increased patient volumes, improved realizations, and capacity expansion.

• Added 623 beds, including new facilities in Noida, Patna, and Ranchi, and expanded clinical talent with 550+ new doctors.

• Noida hospital fully operational with 382 beds, contributing to network expansion but incurring initial EBITDA losses.

• Mature hospitals delivered steady results, while developing hospitals, especially Noida, showed strong ramp-up momentum.

• Board recommended a final dividend of INR 0.50 per share, subject to shareholder approval.

Financial highlights

• FY2026 total income grew 20% year-on-year to INR 45,089 million; EBITDA (ex-Noida) rose 19% to INR 11,343 million with a margin of 25.7%.

• EBITDA including Noida was INR 10,560 million (margin 24.2%), reflecting early-stage losses at Noida.

• Consolidated profit after tax increased 15.1% year-on-year to INR 5,541 million.

• Q4 FY2026 revenue reached INR 11,958 million, up 25% year-on-year; EBITDA (ex-Noida) up 27% to INR 3,142 million.

• ARPOB for FY2026: INR 66,550 (+6.1% y-o-y); ALOS: 3.04 days.

Outlook and guidance

• Noida facility expected to break even in the second half of FY 2027 as occupancy ramps up.

• Over INR 45,000 million capex planned for the next five years, targeting expansions in Delhi, Mumbai, Guwahati, and Varanasi.

• Maintenance capex of INR 6,000 million over three years; expansion to be funded by internal accruals and debt.

• CapEx guidance: INR 800–900 crore for FY 2027, INR 600–700 crore for FY 2028.